

Thyroid Disease Committee meeting 7

Date: 20 September 2018

Location: NGC Boardroom, Royal College of Physicians

Minutes: Final

Committee members present:		
Sarah Fishburn (SF) (Chair)		(Present for notes 1 – 5)
Anh Tran (AT)		(Present for notes 1 – 5)
Annette Furley (AF)		(Present for notes 1 – 4.2)
Bijay Vaidya (BV)		(Present for notes 1 – 5)
Jean Munday (JM)		(Present for notes 1 – 5)
Kristien Boelaert (KrB)		(Present for notes 1 – 5)
Mary Newton (MN)		(Present for notes 1 – 5)
Philip Newland Jones (PNJ)		(Present for notes 1 – 5)
Renee Hoenderkamp (RH)		(Present for notes 1 – 5)
Renuka Dias (RD)		(Present for notes 1 – 5)
Simon Pearce (SP)		(Present for notes 1 – 5)
Timothy Cheetham (TC)		(Present for notes 1 – 5)
Cooptees present:		
Glenn Flux (GF)		(Present for notes 1 – 5)
Huw Griffiths (HG)		(Present for notes 1 – 5)
Mark Ballard (MB)		(Present for notes 1 – 5)
Rowena Jones (RJ)		(Present for notes 1 – 5)
In attendance:		
Catherine McEvoy (CM)	Guideline Commissioning Manager	(Present for notes 1 – 5)
Rupert Franklin (RF)	Guideline Commissioning Manager	(Present for notes 4 – 5)
Carlos Sharpin (CS)	Associate Director/Guideline Lead	(Present for notes 1 – 5)
James Gilbert (JG)	Senior Research Fellow	(Present for notes 1 – 5)
Melina Vasileiou (MV)	Research Fellow	(Present for notes 1 – 5)
Shama Mahammed (SM)	Health Economist	(Present for notes 1 – 5)
Tamara Diaz (TD)	Project Manager	(Present for notes 1 – 5)
Apologies: None		

1. Welcome, apologies and objectives of the meeting

The Chair welcomed the Committee members and attendees to the seventh meeting of the Thyroid Disease Guideline Committee.

The Chair informed the Committee that there were no apologies received. Observers of the day's meeting were introduced to those present.

The Chair outlined the objectives of the meeting.

2. Declarations of interest

Committee Declarations of Interest			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
GF	Research publication on the use of Radioiodine in Benign thyroid conditions (in press). The article recommends a patient specific approach in some cases to minimise unnecessary radiation exposure and to increase the possibility of normal thyroid function.	Direct Specific Non-financial	Declare and participate. Participation in future meetings will be assessed on a meeting by meeting basis.
BV	Elected member of the Executive Committee of the European Thyroid Association	Specific Direct Non-financial	Declare and participate.
PNJ	Final draft of publication of the Regional Medicines Optimisation Committee (South) on the combination use of T3 and T4 in combination acting as clinical input into the guideline.	Direct Specific Non-financial	Declare and participate. Participation in future meetings will be assessed on a meeting by meeting basis.
RD	To speak at British Thyroid Foundation next year.	Direct Specific Non-financial	Declare and participate.
AT	Article titled 'Thyroid hormone replacement in primary care and the Goldilocks principle - too much, too little or just right?' submitted for publication in Prescriber journal. The article reported the outcome of a multi-practice audit on thyroid hormone replacement in primary care	Direct Non-specific Financial	Declare and participate.
	Editorial titled 'thyroid hormone replacement in the preconception period and pregnancy: addressing the challenges in primary care' submitted to British Journal of General Practitioners	Direct Non-specific Non-financial	Declare and participate.
	Abstract titled 'Improvements in monitoring and biochemical control of hypothyroidism in primary care with the use of an electronic protocol: 12-month follow up' submitted for poster presentation at the Society for endocrinology annual conference in November 2018	Direct Non-specific Non-financial	Declare and participate.
TC	Protocol paper of RIG-D study submitted to BMJ open	Direct Non-specific	Declare and participate.

	Adjuvant Rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single arm, single stage, phase II trial	Non-financial	
MN	Giving advice on patient information sheet for Apitope drug trial.	Direct Non-specific Non-financial	Declare and participate
	Expert by experience on Medicines safety project Eastern Academic Health Science Network	Direct Non-specific Non-financial	Declare and participate.
	British Thyroid Foundation Trustee	Direct Non-specific Non-financial	Declare and participate.
DH	Director of Cambridge Supraregional Assay service for investigation of unusual thyroid function tests.	Direct Non-specific Non-financial	Declare and participate.
	Invited to write chapter for Werner and Ingbar's "The Thyroid: A Fundamental and Clinical Text".	Direct Non-specific Non-financial	Declare and participate.
	Invited to mark SfE BES 2018 Abstracts	Direct Non-specific Non-financial	Declare and participate.
	Member of NEQAS specialist advisory group for Hormones and Immunoassay	Direct Non-specific Non-financial	Declare and participate.
RJ	Consultancy fee received from the company producing the product under consideration.	Direct Non-specific Financial	Declare and participate.
	I get paid for carrying out occasional mental health act assessments out of hours or when on a duty rota.	Direct Non-specific Financial	Declare and participate.
	I carry out occasional independent psychiatric reports for solicitors.	Direct Non-specific Financial	Declare and participate.
SP	"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism" Submitted to Lancet Diabetes and Endocrinology, Results of trial using immunological treatment in Graves' disease.	Direct Specific Non-financial	Declare and participate.
KB	Updates on paper: "PTTG and PBF functionally interact with p53 and predict overall survival in head and neck cancer". Accepted for publication in Cancer Research	Direct Non-specific Non-financial	Declare and participate.
	Updates on paper: "Homozygous loss-of-function mutations in SLC26A7 cause goitrous congenital hypothyroidism". Accepted for publication in JCI Insight	Direct Non-specific Non-financial	Declare and participate.
	Results of TABLET trial: "A randomized trial of levothyroxine in preconception women with thyroid antibodies. Submitted to New England Journal of Medicine. RCT of	Direct Specific Non-financial	Declare and participate.

	levothyroxine in TPO antibody positive women before and during pregnancy		
	<i>“Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism “ Submitted to Lancet Diabetes and Endocrinology, Results of trial using immunological treatment in Graves’ disease.</i>	Direct Non-specific Non-financial	Declare and participate.
	<i>“Adjuvant Rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single arm, single stage, phase II trial”. Submitted to BMJ Open .</i>	Direct Non-specific. Non-financial	Not a medication under consideration in the guideline. Declare and participate.
	Reviewed and corrected patient leaflet for the British Thyroid Foundation on Thyroid Disease and Pregnancy: <i>“Your guide to pregnancy and fertility in thyroid disorders”.</i>	Direct Non-specific Non-financial	Declare and participate.
	Reviewed and corrected patient leaflet for British Thyroid Foundation on use of radioiodine in Benign Thyroid Disorders: <i>“Your guide to treatment of an over-active or enlarged thyroid gland with radioactive iodine”</i>	Direct Specific Non-financial	Declare and participate.
	Asked to join two working parties as Lead Endocrinologist to draft consensus statements amendments to the current BTA cancer guidelines. (i) <i>“Management of low risk thyroid cancer”</i> and (ii) <i>“Use of Tyrosine Kinase Inhibitors in patients with advanced iodine refractory differentiated thyroid cancer and advanced medullary thyroid cancer “</i>	Direct Non-specific Non-financial	Declare and participate.
	Green-Top Guidelines on Thyroid Disease in pregnancy submitted to the RCOG.	Direct Non-specific Non-financial	Declare and participate.
	Asked to debate at Endo 2019 (March) in New Orleans re Universal Thyroid Screening in Pregnancy.	Direct Non-specific Non-financial	Declare and participate.
	BES talk (November 2018) has been scheduled to reveal Tablet trial results (See New England Journal of Medicine note above).	Direct Non-specific Non-financial	Declare and participate.
	Editor for chapter in Oxford Textbook of Endocrinology: <i>“Endocrine disorders in pregnancy”.</i>	Direct Non-specific Non-financial	Declare and participate.
	Part of a working group derived from the British Thyroid Association and the British Endocrine Society responding to queries from CCGs regarding streamlining of T3 prescribing: setting-up a T3:T4 consortium based on calls from various CCGs to get some clarity regarding T3 prescribing	Direct Specific Non-financial	Declare and participate.
	Part of a working group derived from the British Thyroid Association and the British Endocrine Society responding to queries from CCGs regarding streamlining of T3 prescribing: development of a QOL tool to help determine/select who may benefit from	Direct Non-specific Non-financial	Declare and participate.

	T3 replacement – a development in its infancy.		
<p>The DOI register was made available to the Committee. The chair reviewed the DOI register and deemed that none of the original DOIs was in conflict with the agenda topics and clinical questions under discussion at the meeting.</p> <p>NICE DOI policy classifications are:</p> <ul style="list-style-type: none"> • Direct financial specific • Direct financial non-specific • Direct non-financial specific • Direct non-financial non-specific • Non-direct financial specific • Non-direct financial non-specific 			
<p>3. Minutes of GC 5&6: The minutes of Committee Meetings 5&6 were agreed by the committee, pending minor edits to the attendance list.</p>			
<p>4. Presentations and discussion:</p> <p>4.1 The evidence review on ‘Who to Test’ evidence review was presented to the committee by JG and SM. The group discussed the clinical and economic evidence and drafted recommendations for this area.</p> <p>4.2 The evidence review on ‘Thyrotoxicosis monitoring’ was presented to the committee by JG and SM. The group discussed the clinical and economic evidence and drafted recommendations for this area.</p> <p>4.3 The evidence review on ‘Hypothyroidism monitoring’ was presented to the committee by JG and SM. The group discussed the clinical and economic evidence and drafted recommendations for this area.</p> <p>4.4 The evidence review on ‘Subclinical monitoring’ was presented to the committee by JG and SM. The group discussed the clinical and economic evidence and drafted recommendations for this area.</p>			
<p>5. Any other business There being no further business, the meeting ended at 1600.</p>			

Date of next meeting: 21 September 2018

Location of next meeting: Boardroom, Royal College of Physicians